SecBot SecBot
Biotech Drug Report Generated Nov 4, 2026

Enbrel

PFE·PFIZER INC
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and marketed since 1998.
Why 3/10
Enbrel has been FDA-approved since 1998 with no pending PDUFA, pivotal readout, or regulatory decision. It is a mature, declining product for Pfizer (a small part of a $60B+ portfolio). No hard binary catalyst is scheduled in the next 12 months, so the impact score cannot exceed 5.
Actionable Insight NEUTRAL

Enbrel is a mature, declining asset for Pfizer with no upcoming binary catalysts. The key events to watch are the 2028-2029 US biosimilar entry window (Eticovo/Erelzi) and continued erosion of international sales, but neither is a near-term catalyst for PFE stock given Enbrel's small contribution to Pfizer's $60B+ revenue base.

Price Chart

Loading chart...

Executive Summary

Enbrel (etanercept) is a long-approved TNF-inhibitor biologic for autoimmune diseases, originally developed by Immunex and now owned by Amgen (AMGN) in North America. Pfizer (PFE) holds international marketing rights outside the US and Canada through its 2009 Wyeth acquisition. The drug faces structural headwinds: Medicare price negotiation cut its US price by 67% effective January 2026, biosimilars have already crushed international sales, and two FDA-approved US biosimilars (Erelzi and Eticovo) await patent expirations in 2028-2029 to launch. For Pfizer, Enbrel is a legacy product with declining revenue and negligible impact on the company's $60B+ total revenue base.

How It Works

Enbrel is a biologic drug (a protein made from living cells) that acts as a TNF inhibitor. Tumor necrosis factor (TNF) is a naturally occurring protein in the body that drives inflammation in autoimmune diseases. Enbrel works by acting as a decoy receptor: it binds to TNF molecules in the bloodstream and prevents them from attaching to cells, thereby reducing the inflammatory response that causes joint swelling, pain, and skin plaques in conditions like rheumatoid arthritis and psoriasis.

Trial Status

Enbrel has been FDA-approved since November 1998 for five indications: rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. It is a mature, commercially marketed biologic with no active pivotal trials for new indications.

The Two-Sided Case

▲ Bull Case3
Enbrel remains a clinically important biologic with five FDA-approved indications (rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis) and continues to generate meaningful revenue globally.
Amgen's aggressive patent litigation has successfully blocked US biosimilar entry for over a decade, with the latest court rulings pushing the earliest US biosimilar launch to 2028-2029, preserving Enbrel's US market exclusivity for now.
For Pfizer, Enbrel is a low-risk, cash-flow-generating legacy product in international markets where it requires no additional R&D investment.
▼ Bear Case4
Enbrel sales are in structural decline: Amgen reported a 37% year-over-year drop in Enbrel sales in Q1 2026, driven by Medicare's Maximum Fair Price of $2,355/month (a 67% cut from list price) that took effect January 1, 2026.
Biosimilar competition has already crushed international sales (where Pfizer holds rights), with Pfizer's ex-US Enbrel sales falling from a $3.8B peak in 2014 to much lower levels as European biosimilars launched in 2016.
Two FDA-approved etanercept biosimilars (Erelzi and Eticovo) are poised to enter the US market once Amgen's patent protection ends in 2028-2029, which will further pressure pricing and volume.
For Pfizer specifically, Enbrel is a legacy Wyeth-acquisition product with declining international revenue and represents a negligible fraction of Pfizer's total revenue.

Upcoming Catalysts

  • No near-term regulatory catalysts for Enbrel itself. Key events to watch: (1) Resolution of Amgen's patent litigation with Sandoz/Samsung Bioepis determining US biosimilar entry timing (currently expected 2028-2029), (2) Continued sales erosion under Medicare's Maximum Fair Price of $2,355/month, (3) Teva's planned US commercialization of Eticovo biosimilar once patents allow.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

PFIZER INC 8-K PFE ·Originating report

Sources · 12

Hover a chip for the title
1 en.wikipedia.org2 drugs.com3 pharmaphorum.com4 biosimilarsrr.com5 coveredusa.org6 techtimes.com7 drugpatentwatch.com8 patent-analytics.thechemsolver.com9 s206.q4cdn.com10 ftc.gov11 wellhn.com12 gabionline.net